The Combination of Dupilumab with Other Monoclonal Antibodies

INTRODUCTION: Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist indicated for the treatment of moderate-to-severe atopic dermatitis (AD), which could be associated with atopic and non-atopic comorbidities for which concomitant administration of targeted pharmacotherapy including monoclo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisondi, P., Maurelli, M., Costanzo, A., Esposito, M., Girolomoni, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823163/
https://www.ncbi.nlm.nih.gov/pubmed/36355314
http://dx.doi.org/10.1007/s13555-022-00851-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823163/
https://www.ncbi.nlm.nih.gov/pubmed/36355314
http://dx.doi.org/10.1007/s13555-022-00851-6

Ejemplares similares